This content is from: Features
Do India’s compulsory licences violate TRIPs?
The compulsory licence issued to Natco over Bayer’s Nexavar drug in India and Novartis’s case at the Supreme Court could set a precedent for developing countries’ approach to pharma patents. Peter Roderick and Pravin Anand take contrasting positions on the cases
To access our in-house intelligence please request a trial here.
Read this article – and more – for a one-week period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here